WHAT’S IN IT – AND WHY?
By Un-Biased Science
***
***
Share this:
Filed under: Drugs and Pharma | Tagged: Covid vaccine, UnBiased Science |
Ann Miller RN MHA [Managing Editor]
ME-P SYNDICATIONS:
WSJ.com,
CNN.com,
Forbes.com,
WashingtonPost.com,
BusinessWeek.com,
USNews.com, Reuters.com,
TimeWarnerCable.com,
e-How.com,
News Alloy.com,
and Congress.org
PodiatryPrep.org
BOARD CERTIFICATION EXAM STUDY GUIDES
Lower Extremity Trauma
[Click on Image to Enlarge]ME-P Free Advertising Consultation
The “Medical Executive-Post” is about connecting doctors, health care executives and modern consulting advisors. It’s about free-enterprise, business, practice, policy, personal financial planning and wealth building capitalism. We have an attitude that’s independent, outspoken, intelligent and so Next-Gen; often edgy, usually controversial. And, our consultants “got fly”, just like U. Read it! Write it! Post it! “Medical Executive-Post”. Call or email us for your FREE advertising and sales consultation TODAY [678.779.8597] Email: MarcinkoAdvisors@outlook.com
Medical & Surgical e-Consent Forms
ePodiatryConsentForms.comME-P Publishing
Start-Up Advice for Businesses, DRs and Entrepreneurs
“Providing Management, Financial and Business Solutions for Modernity”
Capitalism and Free Enterprise Advocacy
Whether you’re a mature CXO, physician or start-up entrepreneur in need of management, financial, HR or business planning information on free markets and competition, the "Medical Executive-Post” is the online place to meet for Capitalism 2.0 collaboration.
Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
OIG Fraud Warnings
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Waldemar Haffkine:
The vaccine pioneer the world forgot
https://www.bbc.com/news/world-asia-india-55050012?utm_source=pocket-newtab
Dr. David E. Marcinko MBA
LikeLike
State Flu Vaccination Rates for Adults in 2019
1. 13 states had vaccination rates from 32.5% to 41.2%: Alaska, Arizona, Florida, Georgia, Idaho, Illinois, Michigan, Mississippi, Louisiana, Nevada, Tennessee, Texas, Wyoming.
2. 12 states had vaccination rates from 41.4% to 43.7%: Alabama, Arkansas, California, Hawaii, Indiana, Kentucky, Montana, New Mexico, Ohio, Oregon, South Carolina, Utah.
3. 13 states had vaccination rates from 43.8% to 47.7%: Colorado, Delaware, Kansas, Maine, Minnesota, Missouri, New Hampshire, New York, North Dakota, Oklahoma, Vermont, West Virginia, Wisconsin.
4. 11 states plus DC had rates from 47.9% to 50.5%: Connecticut, Washington DC, Iowa, Maryland, Massachusetts, Nebraska, North Carolina, Pennsylvania, Rhode Island, South Dakota, Virginia, Washington.
Notes: From an article entitled, “How Prepared Are States to Vaccinate the Public Against COVID-19? Learning from Influenza and H1N1 Vaccination Programs.” New Jersey not included because of state reporting errors. Rates are for flu vaccinations of adults ages 18 and over.
Source: The Commonwealth Fund, December 3, 2020
LikeLike
UPDATE Oral Agents
Currently, there are three antivirals that seem “promising” in combating COVID-19 in its early stages, according to Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases. The top medication as of right now is molnupiravir from Merck&Co. and Ridgeback Biotherapeutics. Following behind are Pfizer’s antiviral, PF-07321332, and Roche and Atea Pharmaceuticals’ AT-527.
How do these antiviral medications work, exactly?
Essentially, they hinder the virus’s ability to replicate in human cells. Currently, only one antiviral drug, known as remdesivir, has been approved to treat COVID-19. However, it’s not an oral drug and it’s also not intended for widespread use. It’s given to patients who’ve been hospitalized from COVID-19.
Kisha
LikeLike